Elicio Therapeutics, Inc. Board of Directors

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node–targeted AMP peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company is also developing ELI-007, a multivalent lymph node–targeted AMP peptide vaccine to target mutant v-raf murine sarcoma viral oncogene homolog B1 gene mutations found in solid tumors; and ELI-008, a multivalent lymph node–targeted AMP peptide vaccine to target p53 hotspot mutations. The company is headquartered in Boston, Massachusetts.

Mr. Robert T. Connelly

Mr. Robert T. Connelly

CEO, President, Principal Accounting Officer, Principal Financial Officer & Director

Ms. Megan C. Filoon

Ms. Megan C. Filoon

General Counsel, Secretary & Compliance Officer

Ms. Esther Welkowsky

Ms. Esther Welkowsky

Senior Vice President of Clinical Development

Dr. Thian Kheoh Ph.D.

Dr. Thian Kheoh Ph.D.

Senior Vice President of Biometrics

Prof. Darrell J. Irvine Ph.D.

Prof. Darrell J. Irvine Ph.D.

Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board

Mr. Michael DiVecchia

Mr. Michael DiVecchia

Senior Vice President of Operations & Human Resources

Dr. Peter DeMuth Ph.D.

Dr. Peter DeMuth Ph.D.

Chief Scientific Officer

Ms. Joy Seymour

Ms. Joy Seymour

VP & Head of Regulatory Affairs

Dr. Christopher M. Haqq M.D., Ph.D.

Dr. Christopher M. Haqq M.D., Ph.D.

Executive VP, Head of Research & Development and Chief Medical Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.